Online Multi-component Psychological Intervention for Depression, Anxiety and Well-being in 7 Countries
Well-being Online: Internet-based Self-administered Intervention to Reduce Anxiety and Depression Symptomatology: Randomized Clinical Trial in 7 Countries
1 other identifier
interventional
200
6 countries
8
Brief Summary
This study evaluates the effectiveness of an online Multi-component psychological intervention, that is focused on providing self-support to the population of 5 Latin American countries and 2 European Countries. The objectives of the intervention are: 1) To reduce the symptoms of anxiety and depression in the adult population, 2) To increase the levels of subjective well-being.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable anxiety
Started Dec 2022
Typical duration for not_applicable anxiety
8 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 22, 2022
CompletedFirst Posted
Study publicly available on registry
July 5, 2022
CompletedStudy Start
First participant enrolled
December 23, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 23, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2024
CompletedJanuary 18, 2023
January 1, 2023
1 year
June 22, 2022
January 16, 2023
Conditions
Outcome Measures
Primary Outcomes (3)
Decrease in the scores of the Center for Epidemiologic Studies Depression (CESD-R) scale
Center for Epidemiologic Studies Depression (CES-D) is a structured self-report scale for evaluation depression symptoms. This scale assesses the number of depression symptoms within 2 weeks. The scale consists 20 items and contains 4-point score responses (0 to 3) as the following; rarely or none of the time (less than 1 day); some of a little of the time (1-2 days); occasionally or moderate amount of time (3-4 days) and most or all of the time (5-7 days). The total possible range of scores is from 0 to 60 where \^16 is the cut-off point for this scale, and higher scores indicate more symptoms of depression. It is expected a statistically significant decrease (P \< 0.05) in depression symptoms.
1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules
Decrease in the score of the General Anxiety Disorder with 7-items (GAD-7) scale
Is a short scale with items that measure the severity of generalized anxiety disorder symptoms. Responses are based on symptoms perceived during the past week. The questions of this scale are answered in Likert format with 0-3, where the maximum total score is 21. A score between 0 and 4 points indicates that anxiety is not perceived, and a score between 15 and 21 is an indicator of perceived severe anxiety.It is expected a statistically significant decrease (P \< 0.05) in anxiety symptoms.
1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules
Increase in Mental Psychological Well-being, the Warwick-Edinburgh Mental Well-being Scale (WEMWBS)
It consists of 14 items, including hedonic (i.e. affects, life satisfaction) and eudaimonic (i.e. positive relationships, psychological functioning) items, which together measure mental well-being. Each item is responded in a Likert scale (i.e. 1 = none of the time to 5 = all of the time) and the total score ranges from 14 to 70. The higher the score, the higher the mental well-being
Time Frame: 1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules
Secondary Outcomes (7)
Decrease in The Perceived Stress Scale (PSS-10)
1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules
Decrease in the score of The Pittsburgh Sleep Quality Index
1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules
Decrease in the Action Acceptance Questionnaire II (AAQ-II)
1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules
Increase in The Satisfaction with Life scale
1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules
Decrease in the Perceived Deficits Questionnaire or PDQ-5
1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules
- +2 more secondary outcomes
Study Arms (3)
Interactive intervention
EXPERIMENTALThe participants will receive a self-applied intervention composed by 10 sessions following a multi component structure. The participants assigned to this condition will count with interactive resources such as Videos, Online Forum and Exercises embedded on the platform.
non-interactive intervention
EXPERIMENTALSelf-administered treatment with 10 sessions will be provided through care manuals in PDF format within the same web platform. Participants in this group will receive a manual within the platform with the same content of the sessions as the experimental group but in PDF format.
Waiting List group
NO INTERVENTIONThe control condition consists of a 30-day waiting list, in which participants will not be able to access the interventions. After the waiting process, they will be given access to either the interactive intervention or the non-interactive intervention.
Interventions
Multi component Intervention composed 10 sessions following a structure based on Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), Positive Psychology (PP), Mindfulness and Behavioral Activation Therapy (BAT).
Eligibility Criteria
You may qualify if:
- Age 18 years or older
- Completion of 100% of the basal evaluation through the form
- Residence in one of the countries participating in the study
- Fluency/ proficiency in Spanish (Mexico, Ecuador, Chile, Peru and Spain), Dutch or English (Netherlands) or Portuguese (Brazil), depending on the country.
You may not qualify if:
- Participants with severe symptoms of anxiety and/or depression, or they report a diagnosis of a depression and/or an anxiety disorder.
- Participants who self-report having another diagnosed psychiatric comorbidity: personality disorder, psychotic disorder, bipolar disorder, Attention-Deficit/Hyperactivity Disorder, or others.
- Participants taking medication for symptoms of depression and/or anxiety
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Universidad Internacional de Valencialead
- Universidad Autonoma de Ciudad Juarezcollaborator
- University of Guadalajaracollaborator
- Universidad Internacional del Ecuadorcollaborator
- Universidad Santo Tomascollaborator
- Tilburg Universitycollaborator
Study Sites (8)
Universidade Federal da Bahia
Ondina, Brazil
Universidad Internacional de Ecuador
Quito, Ecuador
Universidad Autónoma de Ciudad Juárez
Juárez, Chihuahua, 32315, Mexico
Tecnólogico de Monterrey
Guadalajara, Mexico
Universidad de Guadalajara
Guadalajara, Mexico
University of Tilburg
Tilburg, Netherlands
Instituto Peruano de Orientación Psicológica
Lima, Peru
Universidad Internacional de Valencia
Valencia, Spain
Related Publications (17)
Piqueras Rodríguez, J. A., Martínez González, A. E., Ramos Linares, V., Rivero Burón, R., García López, L. J., & Oblitas Guadalupe, L. A. (2008). Ansiedad, depresión y salud (Anxiety, depression and health). Suma Psicológica, 15, 43-74.
BACKGROUNDPodlogar MC, Rogers ML, Stanley IH, Hom MA, Chiurliza B, Joiner TE. Anxiety, depression, and the suicidal spectrum: a latent class analysis of overlapping and distinctive features. Cogn Emot. 2018 Nov;32(7):1464-1477. doi: 10.1080/02699931.2017.1303452. Epub 2017 Mar 20.
PMID: 28317414BACKGROUNDHofmann SG, Asnaani A, Vonk IJ, Sawyer AT, Fang A. The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses. Cognit Ther Res. 2012 Oct 1;36(5):427-440. doi: 10.1007/s10608-012-9476-1. Epub 2012 Jul 31.
PMID: 23459093BACKGROUNDA-Tjak JG, Davis ML, Morina N, Powers MB, Smits JA, Emmelkamp PM. A meta-analysis of the efficacy of acceptance and commitment therapy for clinically relevant mental and physical health problems. Psychother Psychosom. 2015;84(1):30-6. doi: 10.1159/000365764. Epub 2014 Dec 24.
PMID: 25547522BACKGROUNDBolier L, Haverman M, Westerhof GJ, Riper H, Smit F, Bohlmeijer E. Positive psychology interventions: a meta-analysis of randomized controlled studies. BMC Public Health. 2013 Feb 8;13:119. doi: 10.1186/1471-2458-13-119.
PMID: 23390882BACKGROUNDGal E, Stefan S, Cristea IA. The efficacy of mindfulness meditation apps in enhancing users' well-being and mental health related outcomes: a meta-analysis of randomized controlled trials. J Affect Disord. 2021 Jan 15;279:131-142. doi: 10.1016/j.jad.2020.09.134. Epub 2020 Oct 7.
PMID: 33049431BACKGROUNDEkers D, Webster L, Van Straten A, Cuijpers P, Richards D, Gilbody S. Behavioural activation for depression; an update of meta-analysis of effectiveness and sub group analysis. PLoS One. 2014 Jun 17;9(6):e100100. doi: 10.1371/journal.pone.0100100. eCollection 2014.
PMID: 24936656BACKGROUNDSpitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092.
PMID: 16717171RESULTCarleton RN, Thibodeau MA, Teale MJ, Welch PG, Abrams MP, Robinson T, Asmundson GJ. The center for epidemiologic studies depression scale: a review with a theoretical and empirical examination of item content and factor structure. PLoS One. 2013;8(3):e58067. doi: 10.1371/journal.pone.0058067. Epub 2013 Mar 1.
PMID: 23469262RESULTCohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983 Dec;24(4):385-96. No abstract available.
PMID: 6668417RESULTBuysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.
PMID: 2748771RESULTBond FW, Hayes SC, Baer RA, Carpenter KM, Guenole N, Orcutt HK, Waltz T, Zettle RD. Preliminary psychometric properties of the Acceptance and Action Questionnaire-II: a revised measure of psychological inflexibility and experiential avoidance. Behav Ther. 2011 Dec;42(4):676-88. doi: 10.1016/j.beth.2011.03.007. Epub 2011 May 25.
PMID: 22035996RESULTDiener E, Emmons RA, Larsen RJ, Griffin S. The Satisfaction With Life Scale. J Pers Assess. 1985 Feb;49(1):71-5. doi: 10.1207/s15327752jpa4901_13.
PMID: 16367493RESULTStrober LB, Binder A, Nikelshpur OM, Chiaravalloti N, DeLuca J. The Perceived Deficits Questionnaire: Perception, Deficit, or Distress? Int J MS Care. 2016 Jul-Aug;18(4):183-90. doi: 10.7224/1537-2073.2015-028.
PMID: 27551243RESULTSevilla-Gonzalez MDR, Moreno Loaeza L, Lazaro-Carrera LS, Bourguet Ramirez B, Vazquez Rodriguez A, Peralta-Pedrero ML, Almeda-Valdes P. Spanish Version of the System Usability Scale for the Assessment of Electronic Tools: Development and Validation. JMIR Hum Factors. 2020 Dec 16;7(4):e21161. doi: 10.2196/21161.
PMID: 33325828RESULTWatson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988 Jun;54(6):1063-70. doi: 10.1037//0022-3514.54.6.1063.
PMID: 3397865RESULTTennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, Parkinson J, Secker J, Stewart-Brown S. The Warwick-Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation. Health Qual Life Outcomes. 2007 Nov 27;5:63. doi: 10.1186/1477-7525-5-63.
PMID: 18042300RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Mercedes Almela Zamorano, PhD
Tilburg University
- STUDY CHAIR
Reyna Jazmín Martínez Arriaga, PhD
University of Guadalajara
- STUDY CHAIR
David Villarreal Zegarra, MD
Instituto Peruano de Orientación Psicológica
- STUDY CHAIR
Leivy Patricia González Ramírez, PhD
Tecnologico de Monterrey
- STUDY CHAIR
Adrián Antonio Cisneros Hernández, PhD
University of Guadalajara
- STUDY CHAIR
Marinna Simões Mensorio, PhD
Independent Researcher
- STUDY CHAIR
Rosa Olimpia Castellanos-Vargas, PhD
Universidad Autónoma de Ciudad Juárez
- STUDY CHAIR
Rogéria Lourenço dos Santos, PhD
Independent Researcher
- STUDY CHAIR
Joel Omar González Cantero, PhD
University of Guadalajara
- STUDY CHAIR
Viviana Sylvia Vargas Salinas, PhD
Independent Researcher
- STUDY CHAIR
Joaquín Mateu Mollá, PhD
Universidad Internacional de Valencia
- STUDY CHAIR
Flor Rocío Ramírez Martínez, PhD
Universidad Autónoma de Ciudad Juárez
- STUDY CHAIR
Antonio Carlos Santos da Silva, MD
Universidad Federal da Bahia
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Masking Details
- The patients are not aware that there are another experimental group and a control group. The conditions of the study are only known by the researcher and the Research Ethics Committee of the Universidad Autónoma de Ciudad Juárez.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 22, 2022
First Posted
July 5, 2022
Study Start
December 23, 2022
Primary Completion
December 23, 2023
Study Completion
November 1, 2024
Last Updated
January 18, 2023
Record last verified: 2023-01
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- ICF
- Time Frame
- This data will be available approximately in September 2023 and it will be permanently available. It will be shared in the databases of the journal where the article(s) will be published.
- Access Criteria
- Through the servers of the journal(s) where we will publish the articles.
The information will be available in a private server or in a server of the journal(s) that we will publish the articles that will be the result of this study. The protocol of the study is currently in progress to be published, in this article will be included such study protocol, the informed consent is already shared in the register of clinical trials.